The Bridging Study
The study drug is a potential new treatment for hereditary angioedema (HAE). This is a rare disease that results in fluid retention in different parts of the body.
The purpose of this study is to compare how the study drug is metabolised in healthy Japanese, Chinese and Caucasian (incl. European, Middle Eastern, North African) participants. Ethnicity can impact how medication is processed by the body and this data can help to ensure that patients receive the right dose.
The study drug is an oral tablet. It has previously been administered to 326 volunteers in 14 clinical trials and was generally well tolerated. Participants will receive one tablet per day for 5 days.
The current treatments for HAE are injectable. This study drug is an oral tablet, which is more convenient for patients. It is also hoped that this study drug is more tolerable than the current treatments.
This clinical trial has been approved by an independent ethics committee, and you will be reimbursed for your time.
Call us on 1800 243 733 to discuss your eligibility today!